Biogen BIIB Revenue from anti-CD20 therapeutic programs — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's revenue from anti-cd20 therapeutic programs — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's revenue from anti-cd20 therapeutic programs — total revenue?
- Biogen (BIIB) reported revenue from anti-cd20 therapeutic programs — total revenue of $419.1M in Q1 2026.
- How has Biogen's revenue from anti-cd20 therapeutic programs — total revenue changed year-over-year?
- Biogen's revenue from anti-cd20 therapeutic programs — total revenue increased by 10.8% year-over-year, from $378.2M to $419.1M.
- What is the long-term trend for Biogen's revenue from anti-cd20 therapeutic programs — total revenue?
- Over 4 years (2021 to 2025), Biogen's revenue from anti-cd20 therapeutic programs — total revenue has grown at a 2.9% compound annual growth rate (CAGR), from $1.66B to $1.86B.
- What does revenue from anti-cd20 therapeutic programs — total revenue mean?
- This metric represents the total gross revenue generated from the company's portfolio of anti-CD20 therapeutic programs. It captures the aggregate financial performance of monoclonal antibody treatments targeting the CD20 antigen, which are typically used in oncology and immunology indications. This figure reflects the combined market success of these specific therapeutic assets within the company's broader product pipeline.